https://pubmed.ncbi.nlm.nih.gov/12124172/
CT53518, a novel selective FLT3 antagonist for the treatment of acute myelogenous leukemia (AML)
Up to 30% of acute myelogenous leukemia (AML) patients harbor an activating internal tandem duplication (ITD) within the juxtamembrane domain of the FLT3...